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Abstract
In the present project, we extend the previous studies of Origanum majorana by
evaluating the anti-cancer potential of this plant extract on proliferation of colon
cancer. Toward this, we first evaluated the effect of the plant extract on the
proliferation and DNA damage, in vitro, of the human colon cancer HT-29 cell line.
We also determine the mechanism by which Origanum majorana induced cell death
by this extract using biochemical approach. Our results revealed that O. majorana
inhibited the growth of HT-29 cells by effecting the cells viability. Further work
showed the ability of the extract to cause DNA damage, cell cycle arrest and
apoptotic death through activation of caspase 8 and 3 pathways. In conclusion our
data recommend Origanum majorana is an effective inhibitor for colon cancer
progression and more investigation has to explore the Origanum majorana extract in
vivo.

Keywords: Origanum majorana, HT-2, proliferation, cell viability, DNA damage,
cell cycle, apoptotic cell death.
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)Title and Abstract (in Arabic

الملخص
تأثير مستخلص نبتة األوريجانوماجورانا على خاليا سرطان القولون

حعبخشهزِ األطشوحت ايخذادا نذساساث سابمت اجشٌج عهى َبخت األوسٌجاَىياجىساَا ( ،)O.majoranaبحٍذ
حهذف هزِ انذاساست إنى حمٍٍى يضاداث انسشطاٌ فً هزِ انُبخت عهى ًَى سشطاٌ انمىنىٌ ( .)colon cancerنمذ
حًج دساست حأرٍش هزا انًسخخهص انُباحً عهى ًَى وحهف انحًض انُىوي ( (DNA damageفً انًخخبش عهى
خالٌا سشطاٌ انمىنىٌ نإلَساٌ .كًا حى ححذٌذ كٍفٍت آنٍت عًم هزِ انُبخت عهى لخم انخالٌا انسشطاٍَت باسخخذاو
طشق انكًٍٍاء انحٍىٌت ) .)biochemical approachesوأظهشث َخائج هزِ انذساست أٌ َبخت
األوسٌجاَىياجىساَا ) )O. majoranaربطج ًَى سشطاٌ انمىنىٌ يٍ خالل انخأرٍش عهى حٍىٌت انخالٌا
( (cells viabilityوإضافت إنى رنك أظهشث هزِ انُبت انمذسة عهى إحالف انحًض انُىوي ،و إٌماف دوسة
انخهٍت ( )cell cycle arrestو لخم انخالٌا انًبشيج ) )programed cell death- apoptosisعٍ طشٌك
حفعٍم كاسبٍز  ٨و  .(Caspase8 &3)٣وفً انخخاو فئٌ هزِ انُخائج حىصً بُبخت األوسٌجاَىياجىساَا كًزبظ
يؤرش عهى حمذو وًَى سشطاٌ انمىنىٌ ) (colon cancer progressionوسٍخى إجشاءانًزٌذ يٍ األبحاد
السخكشاف حأرٍش هزا انًسخخهص انُباحً عهى جسى انكائٍ انحً.
مفاهيم البحث الرئيسيةَ :بخت األوسٌجاَىياجىساَا ،سشطاٌ انمىنىٌ ،حٍىٌت انخالٌا ،حهف انحًض انُىوي،
دوسة انخهٍت ،لخم انخالٌا انًبشيج.
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Chapter 1: Introduction
1.1 Cancer
Cancer is a multifactorial disease that is characterized by an abnormal growth of cells
and the migration of those cells from their original site to other sites in the body
(Alberts et al., 2002). Cancer is a major health problem worldwide. It is considered
to be the second leading cause of death in high-income countries (cardiovascular
diseases is the first) and the third leading cause of death in middle- and low-income
countries (after cardiovascular diseases and infectious and parasitic diseases)
(American Cancer Society, 2012b). Statistics from the International Agency for
Research on Cancer (IARC), indicated that 14.1 million cases were diagnosed with
cancer in 2012 worldwide. While total cancer deaths reached 8.2 million in the same
year (International Agency for Research on Cancer, 2012). Terrifyingly the global
burden is expected to grow to 21.7 million new cancer cases and 13 million cancer
deaths by 2030 (American Cancer Society, 2012a). In UAE 1729 cancer incidences
were reported in 2012 (Health Autority, 2012).
There are over 100 types of cancer that have been classified based on their tissue
origin. Carcinomas are types of cancer that originate from epithelial cells. Cancer
that affects the cells of the lymph system is known as lymphoma. Sarcomas are
cancers that occur in mesoderm such as bone and muscles, while adenocarcinomas
are cancers that derived from glandular tissue such as breast (Alberts et al., 2002).
Cancer can be caused by several factors that can be classified into internal and
external factors. Internal factors include genomic instability and mutations that could
occur during DNA replication in addition to different genomic factors. On the other
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hand, external factors include environmental causes such as ultraviolet, diet and
smoking (American Cancer Society, 2012b).
Basic hallmarks of cancer were described in a considerable scientific work by
Hanahan and Weinberg. These hallmarks include abnormal induction of proliferative
signals, over expression of oncogene, cells survive rather than performing apoptosis,
unlimited cell division, angiogenesis (formation of new blood vessels) and tumor
metastasis (migration of the cells from their original site) (Hanahan & Weinberg,
2011). Additional hallmarks are indicated in Figure 1.
Tumors can be classified according to their migration status into benign or
malignant. Benigns are primary tumors consist of abnormal cells that accumulate in a
dormant state which originate in a specific tissue and do not migrate to different
locations (Adams et al., 2010; Teiten, Gaascht et al., 2010). However, malignant
tumors are known to migrate from their primary site, through the extracellular matrix
(ECM), blood, lymph and the endothelium of the affected tissues to develop
secondary tumor (Pecorino, 2012).
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Figure 1: Cancer hallmarks (Hanahan & Weinberg, 2011)
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1.2

Colorectal Cancer

1.2.1

Functions of the Colon

Colon also called the large intestine is an organ of the digestive system that function
to absorb water and store the waste-products of digestion until the body is ready to
empty them out (Elias, 2012). Under normal condition, the colonic epithelium is
renewed constantly by crypt proliferative cells which migrate upward along the
crypt-villi axis as they terminally differentiate (Lipkin, 1973). The average time for
these cells to proliferate is one day, and around 25% of the colonic epithelium is
rejuvenated every day. Moreover, the crypt epithelial cells of the entire colon and
rectum are replaced every three to four days (Lipkin, 1973).

1.2.2

Understanding Colorectal Cancer

Colorectal cancer is one of the most common cancers worldwide. According to the
American Cancer Society, in 2012 colorectal cancer found to be the third most
common cancer in men and the second in women. Approximately, 1.4 million cases
of colorectal cancer occurred in 2012 worldwide. Around 693,900 deaths from
colorectal cancer occurred in 2012 worldwide, which accounts for 8% of all cancer
deaths (American Cancer Society, 2012b). As for UAE, colorectal cancer is
considered to be the third common cancer, and the fourth leading cause of death
among other cancers (Health Autority, 2012).
Colorectal cancer induced from multiple genetic and epigenetic changes leading to
the transformation of colon epithelial cells into invasive adenocarcinomas (Ng & Yu,
2015). In addition, genetics has been attributed to colon cancer to either polyposis or
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non-polyposis syndromes. Polyposis syndrome is the familial adenomatous polyposis
(FAP), which is associated with mutated gene or loss of FAP (also called the
adenomatous polyposis coli (APC) gene (Grady, 2003). Non-polyposis colorectal
cancer (HNPCC) syndrome is hereditary, which is associated with germ-line
mutations in DNA mismatch repair genes (Labianca et al., 2010).

1.3

Apoptosis

1.3.1

Programmed Cell Death or Apoptosis

There are several types of cell death such as autophagy, necrosis and apoptosis.
Apoptosis is a highly regulated process of cell death that is characterized by
morphological changes such as cell shrinkage, membrane blabbing, chromatin
condensation, and nuclear fragmentation (Kerr et al., 1972). The balance between
cell growth, differentiation and cell death for maintenance of cellular homeostasis
(Rupnarain, Dlamini, Naicker, & Bhoola, 2004).
Apoptosis is an effective therapeutic mechanism in cancer therapy by designing
drugs that induce apoptosis in tumor cells without any disturbance to the healthy
tissues (Micheau & Tschopp, 2003; Zouet al., 1999). Cells may be induced to
undergo apoptosis by extracellular signals “death factors” which is considered as an
extrinsic pathway. While the other pathway induced by internal physical or
chemicals signals “oxidative stress or DNA damage” called intrinsic pathway
(Gupta, 2003).
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1.3.1.1 The Extrinsic Pathway
External signals are part of the normal control which insure that individual cells
behave for the good of the organism as a whole, through surviving when they are
needed and killing themselves when they are not. Several extracellular signals
stimulate apoptosis, while other inhibit it (Alberts et al., 2002; Pecorino, 2012).
Some extracellular signals stimulate apoptosis such as death factors. Examples of
death factors are Fas ligand or tumor necrosis factor (TNF) and both received
through transmembrane death receptors such as Fas receptor or TNF receptor
respectively. Fas ligand is bound to the plasma membrane of neighboring cells, while
TNF is a soluble factor. Once ligand bind to the death receptor, the receptor
undergoes conformational changes in-order to transmit the signal into the cell. These
conformational changes lead to the exposure of the death domains which are located
on the cytoplasmic tail of the receptors and enable intracellular adaptor proteins to
bind through their death domains (Micheau & Tschopp, 2003).

Example of

intracellular adaptor proteins are Fas-associated death domain protein (FADD) and
TNF receptor-associated death domain protein (TRADD) (Backus et al., 2002).
These adaptor proteins found to transduce the death signal from the receptor to
caspases. The adapters recruit procaspase-8 molecules through death effector
domains (DEDs). Once all the procaspases-8 molecules close to each other, they
become activated by self-cleavage. Caspase-8 is well-known to link between the
receptor and the apoptotic proteases for that reason it’s called as an initiator caspase
for the extrinsic cascade. All of them together, the death ligands, receptors, adaptors,
and initiators caspases are called death inducing signaling complex (DISC). Caspase
activation is initiated by caspase-8 which in turn activate other caspases which called
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the executioner caspases (caspase 3, 6 and 7). As a result, cleavage of specific target
proteins occur which lead to apoptosis (Pecorino, 2012).

1.3.1.2 The Intrinsic Pathway
Cells can activate their apoptosis program internally, usually in response to injury or
stresses (e.g., DNA damage or lack of oxygen or nutrients). The intracellular
activation of apoptotic pathway occurs through the intrinsic pathway of apoptosis,
which depends on the release of cytochrome c from the mitochondria to the cellular
cytosol. Once it is released into the cytosol it binds to procaspases activation adaptor
protein called apoptotic protease activating factor-1 (Apaf1) (Adrain & Martin,
2001). That causes the oligomerization of Apaf1 into a wheel like heptamer called
apoptosome. Consequently, the apoptosome recruits initiator procaspase proteins
(Procaspase-9) that will be activated to from caspase-9 (cleaved form). The activated
caspase-9 which will activate downstream executioner procaspases to induce
apoptosis (Pecorino, 2012). Figure 2 shows both apoptotic pathways.
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Figure 2: Extrinsic and intrinsic apoptotic pathways (Favaloro et al., 2012)
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1.4 Mitotic Cell Cycle

Cells reproduce via duplicating their contents and dividing into two. This cycle of
division and duplication known as a cell cycle. These processes are defined into two
major phases which are S phase (DNA synthesis and chromosome duplication) and
M phase (chromosome segregation and cell division). The M phase includes two
major events; nuclear division (mitosis) and cell division (cytokinesis) (Alberts et al.,
2002).
Most cell cycles contain additional phases that are called gap phases. These gap
phases provide additional time for chromosomes duplication and segregation that are
needed for cell growth generally. Additionally, these gaps serve as transition
regulators in the cell cycle progression. The first gap phase, G1, found before S
phase, while G2 occurs before M phase (Morgan, 2007).
The central components of the cell-cycle control system that include check points
which regulate the transition from one phase to another are family of enzymes called
cyclin-dependent kinases (Cdks). Cdks belong to serine/threonine protein kinases
which are activated at specific points during cell cycle. They get activated via
binding to regulatory proteins called cyclins. Different cyclin-Cdks complexes are
present at specific stage in the cell cycle and are important to regulate irreversible
phase transition. Any defects in cell cycle regulation can result in developmental
abnormalities and cancerous growth (Keaton, 2007).
The p16 (from INK family) and p21 (from Cip/Kip family) are proteins inhibitors
that involved in regulating cyclin-Cdks activity. The p16 family includes p16, p15,
p18 and p19. While, the p21 family’s members are p2, p27 and p57. These inhibitors
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found to interact with cyclin-Cdks complexes by blocking the ATP-binding site,
therefore disabling their kinase activity which leads to cell cycle arrest (Pecorino,
2012).

1.5 Treatments of Cancer
There are many types of cancer treatments, and these types are depending on the type
of cancer and how advanced it is. These treatments include surgery, chemotherapy,
radiation therapy, hormonal therapy or combined therapy. However, these kinds of
therapies known to have different side-effects. Hence, identification and
development of new chemotherapeutic agents from plants “Phytochemicals” have
gained significant recognition in the field of cancer therapy and become a major area
of experimental cancer research (Lin,et al., 2002). Recently, scientists all over the
world are concentrating on the herbal medicines to fight against cancer. By
understanding the complex synergistic interaction of various constituents of
anticancer herbs, new novel herbal anticancer agents can be discovered and designed
to attack the cancerous cells without affecting normal cells of the body
(Pratheeshkumar, 2012).

1.5.1 Phytochemicals
Plants have been shown to be an excellent source of new drugs, including anticancer
agents. There are convincing evidences from experimental studies that highlighted
the importance of naturally occurring compounds derived from plants in reducing the
risk of several cancers and inhibit the development and spread of tumors. With the
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development of molecular and biochemical isolation and purification techniques,
many anticancer agents derived from plants have been identified and developed.
During the last 20 years, more than 25% of drugs that are used were directly derived
from plants, while the other 25% were chemically altered natural products (Cragg &
Newman, 2000) . Different examples of anticancer drugs derived from plants are
currently in use in clinical fields. These include vinca alkaloids vinblastine and
vincristine that were isolated from Catharanroseus, terpene paclitaxel from
Taxusbrevifolia Nutt., and the DNA topoisomerase I inhibitor camptothecin from
Camptothecaacuminate (Kaczirek et al., 2004). Moreover, there are other types of
promising bioactive compounds derived from plants, are currently in clinical trials or
preclinical trials or undergoing further investigation. Examples include flavopiridol,
roscovitine, combretastatin A-4, betulinic acid and silvestrol. Different studies
mentioned the importance of consuming fruits and vegetables, as a source of
phytochemicals, in reducing the incidence of cancer. These includes vitamins
(carotenoids) and food polyphenols, flavonoids, phytoalexins, phenolic acids indoles
and sulfur rich compounds (Vági et al., 2005). The advantage of using such
compounds for cancer treatment is their non-toxic nature. An ideal phytochemical is
one that has anti-tumor properties with minimal or no toxicity and has a defined
mechanism of action.

1.5.1.1 Origanum majorana
One of these plant used for their availability of phytochemicals is Origanum
majorana which belongs Lamiaceae family. Commonly known as marjoram. A large
number of known species of the genus Origanum are used worldwide as spices and
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has a long history of both culinary and medicinal use. O. majorana is used as a home
cure for chest infection, stomach disorders, cough, nervous disorders, sore throat,
rheumatic pain, cardiovascular diseases, and skin care (Al-Harbi, 2011; Vági et al.,
2005). Several studies used marjoram species both in vitro and in vivo approaches.
These studies indicated that O. majorana is very rich in phenolic compounds. The
high phenolics content in Origanum has a capacity to scavenge free radicals and is
shown to be associated with strong antioxidant activity (Miron, Plaza, Bahrim,
Ibáñez, & Herrero, 2011). O. marjorama was shown to contain phenolic terpenoids
(thymol and carvacrol), tannins, flavonoids (diosmetin, luteolin, and apigenin),
phenolic glycosides (arbutin, methyl arbutin, vitexin, orientin, and thymonin),
hydroquinone, and triterpenoids (ursolic acid and oleanolic acid) (Tsimogiannis,
Stavrakaki, & Oreopoulou, 2006). In addition, O. majorana has been reported to
exhibit a significant anti-microbial activity (Leeja & Thoppil, 2007). Several studies
have also revealed that ethanolic, aqueous extracts and essential oil of O. majorana
could protect against kidney and liver damage and genotoxicity induced by lead
acetate (I. El-Ashmawy, 2014; I. M. El-Ashmawy, El-Nahas, & Salama, 2005; I. M.
El-Ashmawy, Saleh, & Salama, 2007). O. majorana has also been shown to inhibit
platelet adhesion aggregation and secretion (Yazdanparast & Shahriyary, 2008). A
study by Al Harbi shows that extract of O. majorana reduced the side effects of
cyclophosphamide, an established anticancer drug, without altering its cytotoxicity
(Al-Harbi, 2011).
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1.5.1.2 Origanum majorana and Cancer
In previous studies, it has been shown that Origanum majorana extract (OME) was
able to inhibit the proliferation of the MDA-MB-231 breast cancer cell lines in time
and concentration-dependent manner. By using deferent concentrations, OME elicits
different effects on the MDA-MB 231 cells (I. M. El-Ashmawy et al., 2007). Low
concentration induced an accumulation of apoptotic –resistant population of cells
arrested in mitosis and overexpressing the cyclin-dependent kinase inhibitor, p21 and
the inhibitor of apoptosis, survivin. On the other hand, higher concentration of OME
triggered a massive apoptosis through the extrinsic pathway, including the activation
of tumor necrosis factor-α (TNF-α), caspase 8, caspase 3, and cleavage of PARP,
downregulation of survivn and depletion of the mutant p53 in MDA-MB-231 cell (Al
Dhaheri, Eid, et al., 2013a). Moreover, it was demonstrated that non-cytotoxic
concentrations of O. majorana significantly inhibited the migration and invasion of
the MDA-MB-231 cells as shown by wound-healing and matrigel invasion assay.
Also it has been showed that O. majorana induced homotypic aggregation of MDAMB-231 associated with an upregulation of E-cadherin protein and promoter activity.
Furthermore, O. majorana decreased the adhesion of MDA-MB-231 to HUVECs
and inhibited transendothelial migration of MDA-MB-231 through TNF-α-activated
HUVECs. Gelatin zymography assay showed that O. majorana suppressed the
activities of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9). ELISA, RTPCR and Western blot results revealed that O. majorana decreased the expression of
MMP-2, MMP-9, urokinase plasminogen activator receptor (uPAR), ICAM-1 and
VEGF. Further investigation revealed that

O. majorana suppressed the

phosphorylation of IκB, down-regulated the nuclear level of NFκB and reduced
Nitric Oxide (NO) production in MDA-MB-231 cells. Most importantly, we also
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showed that Origanum majorana promoted tumor growth inhibition and blocked
metastasis in vivo using chick embryo tumor growth assay (Al Dhaheri, Attoub, et
al., 2013) .
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Chapter 2: Materials and Methods

2.1 Preparation of O. majorana Extracts
Dried leaves of the plant (5.0 gm) were ground to powder by using mortar and pestle.
Then, the fine samples were embedded in 100ml of 70% ethanol and kept in dark at
4ºC. This combination was refrigerated without stirring. After for 72 hours, the
mixture was filtered and evaporated at room temperature. The green residue was
vacuumed for 2–3 hours. Finally, the extract mass was recorded.

2.2 Cell Culture
Human cancer cell lines HT-29, were maintained in DMEM cell growth medium
completed with 10% fetal bovine serum and 100U/ml penicillin/streptomycin and LGlutamine. Cells were maintained in a humidified incubator at 37°C in a 5%
CO2atmosphere.

2.3 Cell Viability
Cancer cells were seeded at a density of 6,000 cells / well in 96-well plates. After 24
h, cells were treated for various time (24, 48 or 72h) with increasing concentrations
of the O. majorana extract (0, 75, 150, 300, 450, 600µg/ml). Experiments were
carried out in triplicate and repeated 5 times. Control cells were treated with vehicle
(ethanol). The effect of drugs on cell viability was determined using cytotoxicity kit
(ABCAM) according to the manufacturer instructions and the results were measured
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using microplate reader. The data presented as proportional viability (%) by
comparing the treated group with the untreated cells, the viability of which is
assumed to be 100%.

2.4 Western Blot
Western blot technique was used to detect the expression levels of several proteins
involved in cell death, DNA damage as well as cell cycle regulators. Proteins were
extracted from treated and untreated cells. Using RIPA lysis buffer (25mM Tris•HCl
pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS). The lysates
were centrifuged at 13000 rpm for 30 min. and the supernatants were collected and
protein concentration measurements were performed. Aliquots of the lysates were
separated via SDS–PAGE, and then it was transferred onto a nitrocellulose
membrane. After blocking with 5% non-fat dried milk containing phosphatebuffered saline (PBS) and 0.1% Tween-20 for one hour, the membranes were
incubated overnight with primary antibodies, followed by an additional incubation
with secondary antibodies. A variety of human antibodies were used at different
dilutions according to the manufacturer instruction as primary antibodies, and
secondary antibodies such as horseradish peroxidase-conjugated goat anti-rabbit or
mouse at a 1:5000 dilution. The membranes were then exposed to X-ray film.
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2.5 Statistical Analysis
Results were expressed as means ± S.E.M. of the number of experiments. A
Student’s t-test for paired or unpaired values was performed and a p value of <0.01
was considered statistically significant.
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Chapter 3: Results

3.1 O. Majorana Extract Inhibits the Viability of the HT-29 Colon Cancer Cells
We started our study by testing the effect of Origanum majorana extract (OME) on
colon cancer cells by measuring the viability of these cells using different
concentrations of the extract (0, 75, 150, 300, 450 and 600 µg/mL) on the cultured
HT-29 colon cancer cell line for different incubation periods (Figure 3). Our results
which have been compared to a vehicle containing control have shown that the
exposure of the HT-29 to OME decreased cellular viability in a concentration- and a
time-dependent manner. In the control culture of HT-29 cells which was treated with
ethanol only, cancer cells proliferated in a constant rate. The IC50 (producing halfmaximal inhibition) was approximately 450 µg/mL at 24 h,250 µg/mL at 48 h, and
300 µg/mL at 72h treatment. Obviously, there is a decline in the number of the viable
cells treated with the (OME) depending on the time and concentration.
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Figure 3: Effect of O. majorana on cell viability of colon cancer HT-29. Cell
viability in percent after incubation with the indicated concentrations of OME
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3.2 O. majorana Extract Induces Morphological Changes in HT-29 Colon
Cancer Cells.
The observation of the OME-treated HT-29 cells based on light microscopy also
showed that the number of treated cancer cells decreased when the concentration of
drug increased. Furthermore, under light microscopy observation of HT-29 cells
treated with various concentrations of 150, 300, 450 and 600 µg/mL OME. Cells
underwent morphological changes which occurred after 48 hours of treatment such
as rounding and shrinkage, which are characteristic of apoptosis as shown in Figure
4.
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Figure 4: Morphological changes in HT-29 cells treated with OME. Morphological
changes observed in the treated HT-29 cells after 48 hours. Images taken at 40x and
400x magnifications. Cells were examined under EVOS XL Core Cell Imaging
System (Life Technologies)
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3.3 Origanum majorana extract induces cell death (apoptosis) in HT-29 colon
Cancer Cells through caspase 3activation
Caspase 3 is considered as one of the most important executioner caspases in
apoptosis which causes cell death. As shown in Figure 5, after exposure of HT-29
cells to OME, our experiment revealed that there is a basic level of caspase 3 in the
control cells. However, there was an increase in the activecaspase 3 level in the
treated cells especially at concentration of (300 µg/ml 450 µg/ml and 600ug/ml)
which means there is cell death caused by caspase 3 activation.
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Figure 5 : An increase in the level of caspase 3 in cells treated with OME treated
cells. Cells were treated with or without increasing concentrations of OME for 48 hr.
Western blot analysis was carried out using anti-cleaved caspase 3
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3.4 Significant induction of apoptosis by O.majorana extract in HT-29 cells.
To further confirmation the induction of apoptosis using OME on HT-29 cell, we
decided to investigate PARP expression in the treated cell. Because PARP is
considered as an apoptosis marker, cells were treated with different doses for 48h. As
shown in figure 6, a high accumulation of cleaved PARP was detected in
concentrations (300, 450 and 600 µg/mL of OME) which confirm the occurrence of
apoptosis.
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Figure 6: Induction of apoptosis by O.majorana extract in HT-29 cells. Cells were
treated for 48 hr. with different concentrations of the OME extract and proteins were
extracted. Western blot analysis was carried out using anti-cleaved PARP antibodies
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3.5 Origanum majorana Extract Activates the Extrinsic Pathway for Apoptosis
via down regulation of Pro-caspase 8.
After we explored the activity of caspase 3 induced by OME, we decided to
determine the cell death pathway if it’s extrinsic or intrinsic by examining the
activity of the initiator caspase. Therefore, we investigated the activity of pro-caspase
8, the inactive form, in different OME concentrations on HT-29. Interestingly, we
found that after 48h of treatment, pro-caspase 8 level decreases in a concentration
dependent manner (Figure 7). As a result, that lead to the increase of active form of
caspase 8 (cleaved form). Therefore, we concluded that OME induce apoptosis
through extrinsic pathway.
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Figure 7: A decrease in the expression of pro-caspase 8 in cells treated with OME
treated cells. Cells were treated with or without increasing concentrations of OME.
Western blot analysis was carried out using anti-pro-caspase 8.
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3.6 Origanum majorana Leads to Upregulation of p21 in treated HT-29 cells
By western blot analysis, we observed an up-regulation in the expression of p21 in
the treated cells. Actually, the cell cycle (in normal cases) occurs in a checked matter
in the presence of regulator proteins, CDK and cyclin. CDK protein becomes active
when it binds to cyclin. In cancer cells, there is uncontrolled cell division. Hence, the
role of CDK inhibitor protein P21 plays a critical role in inducing cell cycle arrest.
P21 binds to CDK and stops its activity by inhibiting cyclin binding. Abbas and
Dutta showed that p21 might has a role in promoting apoptosis via both p53independent and p53-dependent mechanisms below certain cellular stresses and
responses. However, the exact role of how p21 promotes apoptosis is not yet clear.
Nonetheless could depend on both p53-independent and p53-dependent upregulation of the proapoptotic protein BAX, effects on DNA repair or activation of
members of the TNF family of death receptors (Gartel, 2005). Different studies
showed a pro-apoptotic role for p21, it was revealed only that apoptosis coexisted
with induction of p21 without defining whether p21 is needed for the induction of
apoptosis. Therefore, a careful analysis is required to explore the exact role of p21
under these conditions.Upon applying different concentrations of OME, low
concentration of OME (150 µg/mL of OME) did not show any induction of p21
compared to higher concentrations. Upregulation of p21 protein started with higher
dose of OME (Figure 8). Based on that, we can demonstrate that p21 expression
contributes to the cell cycle arrest and also to apoptosis(Abbas & Dutta, 2009).
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Figure 8: Expression levels of p21 in O.majorana-treated HT-29 cells. Cells were
treated with or without increasing concentrations of OME. Western blot analysis was
carried out using anti-p21 antibody
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3.7 Detection of γH2AX, a Marker of DNA fragmentation, in Treated HT-29
Cells with O. majorana Extract
Finally, we wanted to investigate whether OME caused DNA damage in HT-29 cells.
HT-29 cells were treated with either ethanol (control) or various concentrations of
OME (150, 300, 450 and 600 mg/mL). After 48 h, the level of γH2AX was measured
to indicate the DNA damage. A Western blotting analysis revealed a concentrationdependent increase in the levels of γH2AX in response to OME treatment (Figure 9),
this can be explained by the accumulation of double strand DNA breaks in these
cells.
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Figure 9: O. majorana extract induces a dose-dependent activation of γH2AX, a
marker of DNA double-strands breaks in HT-29 colon cancer cells. Western blot
analysis of γH2AX in HT-29 cells exposed for 48h with the indicated concentrations
of OME or equal volume of vehicle (ethanol) as control
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Chapter 4: Discussion
Nowadays, finding a balance in cell proliferation expected to be a master key in
homeostatic maintenance by inhibiting uncontrolled cells proliferation. Through
arresting the cell cycle and induction of apoptosis in progressed cancer cells. An
increasing number of evidences focused on the importance of phytochemicals and
their effect in the metastasis of different cancers including colon cancer. At this
study, we have illustrated that the Origanum majorana extract inhibited the
proliferation of the colon cancer cell line HT-29. We have investigated a cell death
mechanism which inhibit the cell cancer growth.
Firstly, we studied cell viability of treated cells with O. majorana extract. We have
shown a significant cytotoxic effect of the OME on the HT-29 which was in time and
dose manners. Morphological changes were detected on the treated cells which
revealed that colon cancer cells went through cell death. Consequently, we tried to
investigate the mechanism that caused the cell death.
Our data based on experimental molecular studies demonstrated that O. Majorana
extract induced a cell cycle arrest linked with a high expression of P21. OME
triggered the apoptotic cell death by activation of caspase 8 as we showed that by
detecting the level of caspase 8 as a marker of extrinsic pathway. Furthermore, we
revealed a DNA damage by a high expression of γH2AX.
Apoptosis is a very important cell death process that kill cancer cells in two different
pathways, either extrinsic pathway or intrinsic pathway which can be characterized
by the caspases that are stimulated and activated in the cells. In general, the extrinsic
pathway triggered by binding of the ligands with their receptors such as TNF-α and
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Fas (Pecorino, 2012). The death receptors ligation with their ligands activate caspase
8 and this event consequently activate caspase 3 which lead to PARP cleavage and
ultimately apoptosis (Gupta, 2003). In our study, we found that O.majorana extract
inhibited the colon cancer cells growth by activation of caspase 8. In our
experiments, the level of procaspase 8 was very high at the control then it started to
decrease with higher concentrations of OME, that means procaspase-8 has been
cleaved into its active form which is caspase 8.
Actually, caspase 3 is activated by both pathways of apoptosis, extrinsic and intrinsic
and it leads to an effective destruction of the cell followed by a death. Apoptotic cell
death is caspase mediated through the cleavage of multiple proteins crucial in
cellular functioning (Fischer, Jänicke, & Schulze-Osthoff, 2003). For further
conformation of apoptosis, cleavage of PARP should be detected (Kaufmann,
Desnoyers, Ottaviano, Davidson, & Poirier, 1993; Tewari et al., 1995). PARP is
known to have an essentialrole in DNA damage detection and repair. Therefore cells
with damaged DNA have amplified PARP (Herceg & Wang, 1999; Lemaire,
Andréau, Souvannavong, & Adam, 1998).
We wanted to highlight the cleavage of PARP in our treated cells. PARP inhibition is
found to be related to many cellular alterations. However, PARP fragments detected
by western blot is recognized as biomarkers for specific protease activity in
programed cell death. As shown in our results, PARP cleavage was increase
dramatically with dose dependent manner.
On the other hand, DNA damage is estimated as one of the molecular signals
associated with cell cycle arrest and apoptosis. So, we measured the level of γH2AX
to assess the DNA damage. Successfully, we found that γH2AX accumulated in high
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concentrations in OME treated cells. Our result demonstrates that OME caused a
double stranded DNA damage in a concentration dependent manner.
Alongside with DNA damage and cell cycle arrest, we liked to explore if DNA
damage is leading to a cycle arrest. p21 plays a major role in inhibiting CDK which
leads to a growth arrest. Therefore, we studied the expression of the CDK inhibitor,
p21, in treated HT-29. Interestingly, an increase expression of P21 was detected in
the treated cells. The cycle cell arrest or in other word the growth arrest is correlated
with apoptosis in most cases of cell death (Sambucetti et al., 1999).
In previous study, a team of the lab have demonstrated that the Origanum majorana
extract inhibited the proliferation of the mutant p53 triple negative breast cancer
(TNBC) cell line, MDA-MB-231. They induced a cell cycle arrest at G2/M phase and
this cell cycle arrest correlates with an overexpression of the CDK inhibitor p21. Growth
arrest is successfully induced by OME in our present study with a need of more exploring in
investigating the expression of CDK inhibitor.

By the previous study data, At high

concentrations of OME, apoptosis was induced via activating the cell death extrinsic
pathway which was mediated by the activation of TNF-α and activation of caspase 8. They
have also shown that apoptosis is also mediated by an increase in DNA damage, revealed by
the expression of γH2AX, (Al Dhaheri, Eid, et al., 2013b). We have shown the same results

of the OME effect in activating the extrinsic apoptotic pathway and how this extract
induces DNA damage in human colon cancer cells HT-29 cell line. The similarity in
our present study results and the previous study data on the effect of OME on
different human cancer cells confirms the efficiency of the extract in inhibition the
cancer cells growth and more study and careful experiments are needed to be done in
the future to explore more pathways and mechanisms induced by this plant extract.
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In conclusion, our study demonstrated that Origanum majorana extract effects HT29 in concentration-dependent manner. At high concentrations, OME induced DNA
damage indicated by the upregulation of γH2AX and this DNA damage leads to
growth arrest. Moreover, DNA damage also induced an extrinsic apoptosis pathway,
mediated by activation of procaspase 8 which is connected to PARP cleavage
through caspase3. The suggested apoptosis pathway of OME on HT-29 is shown in
the model (Figure 10).
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Figure 10: The proposed model shows the effect of Origanum majorana on HT-29
human colon cancer cells
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Chapter 5: Conclusion
In conclusion, we have illustrated that the Origanum majorana plant extract effect
the colon cancer cell line HT-29 successfully by inducing DNA damage and growth
arrest. Furthermore, our data have shown the potential of this treatment in activating
apoptosis in the colon cancer cells. In future, we are looking for further laboratory
research and investigations to study the effect of OME on the HT-29 cells migration
to confirm the capacity of OME in inhibiting colon cancer metastasis.
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